(Z) -Orantinib

(Z) -Orantinib ((Z) -SU6668) is a potent, selective, orally active and ATP competitive inhibitor of Flk‐1/KDR, PDGFRβ, and FGFR1, with IC50s of 2.1, 0.008, and 1.2 μM, respectively. (Z) -Orantinib is a potent antiangiogenic and antitumor agent that induces regression of established tumors[1][2].

Product Specifications

CAS Number

[210644-62-5]

Product Name Alternative

(Z) -SU6668; (Z) -TSU-68

UNSPSC

12352005

Hazard Statement

H302, H315, H319, H335, H413

Target

FGFR; PDGFR; VEGFR

Type

Reference compound

Related Pathways

Protein Tyrosine Kinase/RTK

Applications

Cancer-Kinase/protease

Field of Research

Cancer

Assay Protocol

https://www.medchemexpress.com/z-orantinib.html

Concentration

10mM

Purity

99.44

Solubility

DMSO : 50 mg/mL (ultrasonic)

Smiles

O=C(O)CCC1=C(C)NC(/C=C2C(NC3=C\2C=CC=C3)=O)=C1C

Molecular Formula

C18H18N2O3

Molecular Weight

310.35

Precautions

H302, H315, H319, H335, H413

References & Citations

[1]Laird AD, et, al. SU6668 is a potent antiangiogenic and antitumor agent that induces regression of established tumors. Cancer Res. 2000 Aug 1;60 (15) :4152-60.|[2]Laird ad, et, al. SU6668 inhibits Flk-1/KDR and PDGFRbeta in vivo, resulting in rapid apoptosis of tumor vasculature and tumor regression in mice. FASEB J. 2002 May;16 (7) :681-90.